Skip to content
Home>Investor Relations>Blog>Balchem Corporation Completes Acquisition of Kappa Bioscience AS

Balchem Corporation Completes Acquisition of Kappa Bioscience AS

Posted: June 21, 2022
Blog | Investor Relations | Press Releases

Balchem Corporation announced that it completed its acquisition of Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway. The signing of a definitive agreement to acquire Kappa Bioscience AS was previously announced on June 14, 2022.

View Press Release

Related Posts

Balchem Corporation Signs Definitive Agreement to Acquire Kappa Bioscience AS
Balchem has signed a definitive agreement to acquire Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway.
Balchem Corporation Reports First Quarter 2022 Financial Results
Ted Harris, Chairman, CEO, and President of Balchem said, “We are very pleased to have continued the strong momentum from 2021 into 2022. In the first quarter of 2022 we delivered all-time record sales, adjusted net earnings, and adjusted EBITDA in a very difficult macro-economic and geo-political environment.”